Oct 28 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will pay Monte Rosa Therapeutics (GLUE.O), opens new tab $150 million upfront payment for a global license to develop ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...

Novartis NOVN-0.15%decrease; red down pointing triangle raised its guidance for the third time this year after higher third-quarter results topped expectations, boosted by revenue from its ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication. The Swiss drugmaker ...

A bitter and bloody war in Ukraine has devastated the country, further isolated Russia from the West and fueled economic insecurity around the world. Officials said more than 30 drones had been ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

Russians close to the Kremlin voiced optimism that Donald J. Trump could help end the war in Ukraine on Russia’s terms. Vladimir V. Putin said Mr. Trump’s remarks on ending the war “deserve ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

Swiss pharmaceutical giant Novartis reported another solid quarter on Tuesday, raising its guidance for the third time this year. Yet its shares were the worst performers among big pharma ...